



Intarcia Ref. No. INT 004.10
USSN 10/004,118
PATENT

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Printed Name Gary R. Fabian
Signature Gary R. Fabian Date of Deposit 17 July 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stanford Mark Moran	Confirmation No. 8022
Serial No.: 10/004,118	Art Unit: 1647
Filing Date: 30 October 2001	Examiner: Seharaseyon, J.
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON	

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-referenced application are the following documents:


1. Transmittal;
2. Modified Form 1449 and copies of 27 non-US Patent publications;
3. Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97;
4. Certificates of First Class Mailing; and
5. Return Receipt Postcard.

Authorization to Charge Deposit Account.

No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** (please reference **INT 004.10**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Dated: 17 July 2007

By : 
Gary R. Fabian, Ph.D.
Registration No. 33,875
Agent for Applicant

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dkt No. INT 004.10



FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 1 of 6

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Name	Date	Class	Sub Class	Filing Date
	A-01	4,211,771	Witkowski et al.	07/08/1980			
	A-02	4,695,623	Stabinsky	09/22/1987			
	A-03	4,727,138	Goeddel et al.	02/23/1988			
	A-04	4,762,791	Goeddel et al.	08/09/1988			
	A-05	4,820,638	Swetly et al.	04/11/1989			
	A-06	4,845,196	Cowling	07/04/1989			
	A-07	4,897,471	Stabinsky	01/30/1990			
	A-08	4,915,954	Ayer et al.	04/10/1990			
	A-09	4,917,895	Lee et al.	04/17/1990			
	A-10	4,929,554	Goeddel et al.	05/29/1990			
	A-11	4,976,966	Theeuwes et al.	12/11/1990			
	A-12	5,004,689	Fiers et al.	04/02/1991			
	A-13	5,112,614	Magruder et al.	05/12/1992			
	A-14	5,120,832	Goeddel et al.	06/09/1992			
	A-15	5,221,278	Linkwitz et al.	06/22/1993			
	A-16	5,231,176	Goeddel et al.	07/27/1993			
	A-17	5,318,558	Linkwitz et al.	06/07/1994			

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 2 of 6

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Name	Date	Class	Sub Class	Filing Date
	A-18	5,324,280	Wong et al.	06/28/1994			
	A-19	5,368,863	Eckenhoff et al.	11/29/1994			
	A-20	5,413,572	Wong et al.	05/09/1995			
	A-21	5,443,459	Wong et al.	08/22/1995			
	A-22	5,529,914	Hubbell et al.	06/25/1996			
	A-23	5,543,156	Roorda et al.	08/06/1996			
	A-24	5,574,137	Gray et al.	11/12/1996			
	A-25	5,602,010	Hauptmann et al.	02/11/1997			
	A-26	5,660,847	Magruder et al.	08/26/1997			
	A-27	5,690,925	Gray et al.	11/25/1997			
	A-28	5,728,396	Peery et al.	03/17/1998			
	A-29	5,795,779	McCormick et al.	08/18/1998			
	A-30	5,807,876	Armistead et al.	09/15/1998			
	A-31	5,858,746	Hubbell et al.	01/12/1999			
	A-32	5,939,286	Johnson et al.	08/17/1999			
	A-33	5,985,305	Peery et al.	11/16/1999			
	A-34	6,113,938	Chen et al.	09/05/2000			

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 3 of 6

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Name	Date	Class	Sub Class	Filing Date
	A-35	6,129,761	Hubbell	10/10/2000			
	A-36	6,204,022	Johnson et al.	03/20/2001			
	A-37	6,172,046	Albrecht	01/09/2001			

FOREIGN PATENT DOCUMENTS								
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Translation YES NO	
	B-01	WO 03/030923 A1	17-Apr-2003	WIPO/PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	C-01	ADAMSON et al., "Phase I trial and pharmacokinetic study of all- <i>trans</i> -retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer" J Clin Oncol (1997) Nov; 15(11):3330-3337
	C-02	BAILON et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C" Bioconjugate Chemistry (2001), 12(2):195-202

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 4 of 6

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	C-03	DORR et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days" J Interferon Res (1988); 8:717-725
	C-04	FRANCHETTI et al., "Furanfuran and Thiophenfuran: Two Novel Tiazofuran Analogues. Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase" Journal of Medicinal Chemistry (1995); 38(19):3829-3837
	C-05	GAUSE et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer" J Clin Oncol (1996) Aug; 14(8):2234-2241
	C-06	GOSLAND et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha" Cancer Chemother Pharmacol (1995); 37(1-2):39-46
	C-07	HEATHCOTE et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis" New England Journal of Medicine (2000); 343(23):1673-1680
	C-08	HORTON et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999)
	C-09	HUBEL et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia (1997) Dec; 11 Suppl 5:S47-S51
	C-10	IACOBELLI et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer" Am J Clin Oncol (1995); 18(1):27-31
	C-11	ISHIWATA et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs" (1998); J Vet Med Sci 60(8):911-917
	C-12	KIRKWOOD et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684" J Clin Oncol (1996); 14(1):7-17

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Sheet 5 of 6

In the Application of: Stanford Mark Moran
Serial No.: 10/004,118
Filed: 30 October 2001
Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

Confirmation No.: 8022
Art Unit: 1647
Examiner: Seharaseyon, J.

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Exam. Init.	Ref. Desig.	Description
	C-13	MOTZER et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma" Journal of Clinical Oncology (2001); 19(5):1312-1319
	C-14	NEUMANN et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy" Science 282 (1998): 103-107.
	C-15	RAJKUMAR et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma" Int J Radiat Oncol Biol Phys (1998) Jan 15; 40(2):297-302
	C-16	ROTH et al., "High Dose Etretnate and Interferon-alpha--A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas" Acta Oncol (1999); 38(5):613-617
	C-17	SULKOWSKI et al., "Pegylated Interferon Alfa-2A (Pegasys™) and Ribavirin Combination Therapy for Chronic Hepatitis C: A Phase II Open-Label Study" Gastroenterology (2000); 118(4_Suppl_2), Abstract 236
	C-18	TALPAZ et al., "Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia" Blood (2001); 98(6):1708-1713
	C-19	TRUDEAU et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer" Cancer Chemother Pharmacol (1995); 35(6):496-500
	C-20	VOKES et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest" Cancer Chemother Pharmacol (1995); 35(4):304-312
	C-21	ZEUZEM et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C" New England Journal of Medicine (2000), 343(23):1666-1672
	C-22	InterMune® Inc. Infergen® (Interferon alfacon-1). 2002
	C-23	Hoffmann-La Roche Inc. Pegasys® (peginterferon alfa-2a). 2002
	C-24	Roche Pharmaceuticals. ROFERON®-A (Interferon alfa-2a, recombinant). 2003
	C-25	Schering Corporation. Intron® A for Injection. 2001

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dkt No. INT 004.10

FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 6 of 6

In the Application of: Stanford Mark Moran

Confirmation No.: 8022

Serial No.: 10/004,118

Art Unit: 1647

Filed: 30 October 2001

Examiner: Seharaseyon, J.

Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Exam. Init.	Ref. Desig.	Description
	C-26	Schering Corporation. PEG-Intron™ (Peginterferon alfa-2b). Powder for Injection. 2003

Examiner: _____ Date Considered: _____

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Intarcia Ref. No. INT 004.10
USSN 10/004,118
PATENT

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service under 37 CFR §1.8 on the date indicated below and with sufficient postage addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Gary R. Fabian

Printed Name

Signature

Gary R. Fabian

17 July 2007

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Stanford Mark Moran

Confirmation No. 8022

Serial No.: 10/004,118

Art Unit: 1647

Filing Date: 30 October 2001

Examiner: Seharaseyon, J.

Title: METHOD FOR TREATING DISEASES WITH OMEGA INTERFERON

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The information listed below may be material to the examination of the above-identified application. A completed Form PTO-1449 and copies of the cited non-patent references accompany this paper.

Further, because this application was filed after 30 June 2003, copies of cited U.S. Patent and U.S. Patent Application publications have not been submitted pursuant to the waiver described in pre-OG Notice "Information Disclosure Statements may be filed without copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record in the present application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to

the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Authorization to Charge Deposit Account:

The Commissioner is hereby authorized to charge No additional fees are believed due in connection with this paper. However, the Commissioner is hereby authorized to charge to Deposit Account No. **504212** (please reference docket number **INT 004.10**) any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, with the exception of the payment of the Issue Fee.

Respectfully submitted,

Date: 17 July 2007

By: Gary R. Fabian
Gary R. Fabian, Ph.D.
Agent for Applicants
Registration No. 33,875

Intarcia Therapeutics, Inc.
2000 Powell Street
Suite 1640
Emeryville, CA 94608